Viral infection, drug toxicity, and resistance are unwanted outcomes in transplant patients. T cell immune therapy is under investigation as a possible strategy to control new viral infection and reactivation of latent viruses due to immunosuppressive drugs. This new development could also decrease unwanted drug toxicity and resistance.